# A patient with penile metastasis secondary to small cell lung cancer successfully treated with PD-1 inhibitors and chemotherapy: a case report and literature review

**Authors:** Kai-cong Zhang, Wei-jun Li, Hui-xin Xu, Hui-min Liang, Qiong Yang

PMC · DOI: 10.3389/fonc.2025.1484365 · Frontiers in Oncology · 2025-02-25

## TL;DR

A rare case of penile metastasis from small cell lung cancer was successfully treated with PD-1 inhibitors and chemotherapy, showing a 2-year survival.

## Contribution

This case report highlights the rare occurrence and effective treatment of penile metastasis from small cell lung cancer.

## Key findings

- Penile metastasis from small cell lung cancer is extremely rare.
- Treatment with PD-1 inhibitors and chemotherapy led to a partial response and 2-year survival.
- Standard small cell lung cancer treatment strategies can be effective for such rare metastases.

## Abstract

Penile metastasis is an uncommon condition, with most primary malignancies originating in the abdominal cavity and pelvis. There have been very few reported cases originating from lung cancer, most of squamous cell carcinoma without small cell lung cancer.

We presented a case of penile metastasis secondary to small cell lung cancer, along with a review of relevant literature from the CNKI database.

A 73-year-old male presented with a one-month history of palpable swelling in the penis without any chest symptoms. Beside penile lesion, PET/CT imaging also revealed a lesion in the left lobe of the lung, as well as multiple enlarged lymph nodes in the left hilum, mediastinum, and left supraclavicular fossa. Fiberoptic biopsy confirmed small cell lung cancer for the pulmonary mass, while biopsies of the penile mass confirmed metastatic small cell carcinoma. The patient received first-line treatment of 6 cycles of PD-1 inhibitor (Toripalimab) combined with etoposide and cisplatin, achieving a partial response (PR). Subsequently, second-line therapy of etoposide and cisplatin regimen and later-line therapies of Irinotecan followed by Anlotinib were administered. The overall survival was approximately 2 years.

Penile metastasis from small cell lung cancer is extremely rare. Treatment strategies based on guidelines for small cell lung cancer had been proven effective approaches.

## Linked entities

- **Chemicals:** etoposide (PubChem CID 36462), cisplatin (PubChem CID 5460033), Irinotecan (PubChem CID 60838), Anlotinib (PubChem CID 25017411)
- **Diseases:** small cell lung cancer (MONDO:0008433)

## Full-text entities

- **Genes:** PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}
- **Diseases:** small cell carcinoma (MESH:D018288), squamous cell carcinoma (MESH:D002294), swelling (MESH:D004487), malignancies (MESH:D009369), penile lesion (MESH:D010409), lung cancer (MESH:D008175), Penile metastasis (MESH:D009362), small cell lung cancer (MESH:D055752), penile mass (MESH:C536030)
- **Chemicals:** cisplatin (MESH:D002945), Irinotecan (MESH:D000077146), etoposide (MESH:D005047), Anlotinib (MESH:C000625192), Toripalimab (MESH:C000656314)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11893422/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11893422/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC11893422/full.md

---
Source: https://tomesphere.com/paper/PMC11893422